Alabama Pharmacist Defense Lawyer – Board of Pharmacy Matter Pending? We Can Help – Maryland Issues New Statewide Standing Order for Pharmacy Naloxone Dispensing; Arizona Requires Pharmacists to Report Naloxone Doses Dispensed to PDMP

5Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Alabama Pharmacist Defense Lawyer – Board of Pharmacy Matter Pending? We Can Help – Maryland Issues New Statewide Standing Order for Pharmacy Naloxone Dispensing; Arizona Requires Pharmacists to Report Naloxone Doses Dispensed to PDMP – (866) 348-2889

In Maryland, Howard Haft, MD, Deputy Secretary for Public Health Services, Department of Health and Mental Hygiene (DHMH), issued a new statewide standing order that allows Maryland-licensed pharmacists to dispense naloxone to anyone who may be at risk for opioid overdose or in a position to assist someone believed to be experiencing opioid overdose. Under the new standing order, which replaces Dr Haft’s original order issued in December 2015, a person-specific paper or electronic prescription is not required for a pharmacist to dispense naloxone. Prior to the new standing order, pharmacists were only authorized to dispense naloxone to individuals who had been trained and certified under the Maryland Overdose Response Program, indicates the DHMH website. The Heroin and Opioid Prevention Effort and Treatment Act of 2017, which simplifies the process for obtaining naloxone from a pharmacy, was signed into law by Governor Larry Hogan on May 25, 2017. Additional information is available for pharmacists in the Guidance for Pharmacy Dispensing.

CLICK HERE TO CONTINUE READING

Posted in Pharmacist | Tagged , , , | Leave a comment

Alabama Pharmacist Defense Lawyer

Alabama Pharmacist Defense Lawyer – Kreps Law Firm, LLC

Alabama Pharmacist Defense Lawyer – Great to be at the Alabama State Board of Pharmacy this morning! Much respect for the people in the pharmacy profession and the people in this building. Always enjoy helping our clients at the Board! – Kreps Law Firm, LLC

Call TODAY! Do not wait! (866) 348-2889

www.alabamapharmacistdefenseattorney.com/Pharmacist_Defense_Attorney.html

Alabama Pharmacist Defense Lawyer, Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

26805_generalcriminal_080816

Pharmacy_graphic_facebook_070616

Posted in Pharmacist | Tagged , , , , | Comments Off

Lawyer for Alabama Pharmacy Board Hearing – Call today to discuss your case – FDA Requests Endo Pharmaceuticals Remove Opana ER From Market for Risks Related to Misuse and Abuse

14774_PHARMACY BOARD_072216Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Lawyer for Alabama Pharmacy Board Hearing – Call today to discuss your case – FDA Requests Endo Pharmaceuticals Remove Opana ER From Market for Risks Related to Misuse and Abuse – (866) 348-2889

Food and Drug Administration (FDA) requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana® ER (oxymorphone hydrochloride), from the market based on the agency’s concern that the benefits of the drug may no longer outweigh its risks related to misuse and abuse. “We are facing an opioid epidemic – a public health crisis, and we must take all necessary steps to reduce the scope of opioid misuse and abuse,” says FDA Commissioner Scott Gottlieb, MD, in an FDA news release. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.

The agency’s decision is based on a review of all available postmarketing data, which demonstrated a significant shift in the route of abuse of Opana ER from nasal to injection following the product’s reformulation. Injection abuse of reformulated Opana ER has been associated with a serious outbreak of HIV and hepatitis C, as well as cases of a serious blood disorder (thrombotic microangiopathy).

CLICK HERE TO CONTINUE READING

Posted in Pharmacist | Tagged , , , , | Comments Off

Alabama Pharmacy Board Defense Lawyer – Call Today – Forty-Two States Now Participating in NABP PMP InterConnect

Alabama Defense Lawyer, Board of 14738_graphic_standard_070616Pharmacy, Pharmacy Defense Attorney, KLF

Alabama Pharmacy Board Defense Lawyer – Call Today – Forty-Two States Now Participating in NABP PMP InterConnect – (866) 348-2889

Pennsylvania recently deployed NABP PMP InterConnect®, bringing the total number of live participating state prescription monitoring programs (PMPs) to 42. PMP InterConnect is a highly secure communications exchange platform that facilitates the transmission of PMP data across state lines to authorized requestors, while ensuring that each state’s data-access rules are enforced.

In addition to Pennsylvania, PMPs from the following states are able to securely exchange prescription data: Alaska, Alabama, Arizona, Arkansas, Colorado, Connecticut, Delaware, District of Columbia, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Montana, Mississippi, Nevada, New Jersey, New Hampshire, New Mexico, New York, North Dakota, Ohio, Oklahoma, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, West Virginia, and Wisconsin. NABP continues to work with other states to facilitate their participation. Additional information about PMP InterConnect is available in the Initiatives section of the NABP website.

CLICK HERE TO CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

Lawyer for Alabama Pharmacy Board Hearing – Call today to discuss your case – FDA Approves First Orally Dissolvable Methylphenidate Tablets for ADHD

04-thanksgiving-fb

Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Lawyer for Alabama Pharmacy Board Hearing – Call today to discuss your case – FDA Approves First Orally Dissolvable Methylphenidate Tablets for ADHD – (866) 348-2889

Officials with the FDA have approved methylphenidate (Cotempla XR-ODT, Neos Therapeutics) extended-release orally disintegrating tablets. The tablets are indicated to treat attention-deficit/hyperactivity disorder (ADHD) in patients aged 6-17 years old.

The approval is based on data from a phase 3 clinical trial that supports the safety and efficacy of Cotempla XR-ODT. In the trial, treatment demonstrated a statistically significant improvement in ADHD symptoms compared to a placebo in children in a laboratory classroom. The drug’s effectiveness was indicated at 1 hour after the dose was received and lasted for 12 hours. No serious adverse events were reported.

CLICK HERE TO CONTINUE READING

Posted in Pharmacist | Comments Off

Lawyer for Alabama Pharmacy Board Hearing – Call today to discuss your case – After FDA approves second infliximab biosimilar, clinicians face decisions

6Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Lawyer for Alabama Pharmacy Board Hearing – Call today to discuss your case – After FDA approves second infliximab biosimilar, clinicians face decisions – (866) 348-2889

In April, FDA approved infliximab-abda (Renflexis, Samsung Bioepis), the second biosimilar for reference biologic infliximab (Remicade, Janssen) after biosimilar infliximab-dyyb (Inflectra, Pfizer). As with infliximab and infliximab-dyyb, infliximab-abda is approved for adult Crohn disease, pediatric Crohn disease, ulcerative colitis, rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. How clinicians choose which agent to use may set the tone for future cases in which more than one biosimilar is approved for a biologic.

The infliximab agents are currently not interchangeable by FDA standards, as the agency released draft guidance on the requirements for that designation only last January. But the approval process for biosimilars should put health providers at ease when making clinical decisions, said James G. Stevenson, PharmD, FASHP, professor in the department of clinical pharmacy at University of Michigan College of Pharmacy in Ann Arbor.

CLICK HERE TO CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

Alabama Pharmacy Board Defense Attorney – Pharmacist Hearing Upcoming? Call Today – Combining vitamin C with antibiotics destroys cancer stem cells

7

Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Alabama Pharmacy Board Defense Attorney – Pharmacist Hearing Upcoming?  Call Today – Combining vitamin C with antibiotics destroys cancer stem cells

A combination of vitamin C and antibiotics could be key to killing cancer stem cells, a new study finds, paving the way for a strategy that could combat cancer recurrence and treatment resistance.

Researchers found that a therapy involving the antibiotic Doxycycline and ascorbic acid, or vitamin C, was up to 100 times more effective for killing cancer stem cells (CSCs) than 2-DG, a molecule currently being tested as an anti-cancer agent in clinical trials.

CLICK HERE TO CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

Alabama Pharmacy Defense Attorney – Hearing Defense – Thirteen Individuals Illegally Diverted Oxycodone for Street Sale With Stolen Prescription Pad

3Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Alabama Pharmacy Defense Attorney – Hearing Defense – Thirteen Individuals Illegally Diverted Oxycodone for Street Sale With Stolen Prescription Pad – (866) 348-2889

Thirteen individuals affiliated with a prescription drug ring that illegally wrote and filled prescriptions for oxycodone and then sold them in Lehigh Valley, PA, were charged with conspiracy to acquire a controlled substance by fraud and related charges. The prescription pad was stolen from St Luke’s Orthopedic Specialists, of Fountain Hill, PA. Data from the Pennsylvania Department of Health’s Prescription Drug Monitoring Program was used to investigate the case and file these charges, indicates Pennsylvania Attorney General Josh Shapiro’s press release.

CLICK HERE TO CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

Alabama Pharmacy Board Defense Attorney – Pharmacist Hearing Upcoming? Call Today – CDC Publishes Guide to Help Pharmacists Initiate CPAs With Prescribers

26799_graphic_standard_080816Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Alabama Pharmacy Board Defense Attorney – Pharmacist Hearing Upcoming? Call Today – CDC Publishes Guide to Help Pharmacists Initiate CPAs With Prescribers – (866) 348-2889

Centers for Disease Control and Prevention (CDC) published a guide that provides pharmacists with information and resources to empower them to initiate collaborative practice agreements (CPAs) with collaborating prescribers. The guide, Advancing Team-Based Care Through Collaborative Practice Agreements: A Resource and Implementation Guide for Adding Pharmacists to the Care Team, contains a sample CPA and sample language that can be customized by pharmacists and prescribers using their specific state laws to create a CPA. Cardiovascular disease and hypertension were used as examples of disease states that can be managed using a CPA, but the concepts presented in the guide can also be applied to many other chronic conditions, treatments for acute illness, and preventive health measures.

CLICK HERE TO CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

Alabama Pharmacist Defense Lawyer – Board of Pharmacy Matter Pending? We Can Help – NACDS and APhA Urge Trump Administration to Reject Broad Drug Importation Proposals and HHS Waiver Authority

7Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Alabama Pharmacist Defense Lawyer – Board of Pharmacy Matter Pending? We Can Help – NACDS and APhA Urge Trump Administration to Reject Broad Drug Importation Proposals and HHS Waiver Authority – (866) 348-2889

The National Association of Chain Drug Stores (NACDS) and the American Pharmacists Association (APhA) urge the Trump Administration to refrain from endorsing pending legislative proposals that would allow for broad personal and commercial importation of non-FDA-approved prescription drugs. In a letter, NACDS and APhA also ask the Secretary of Health and Human Services (HHS) to not exercise the waiver authority that allows the Secretary to waive the general prohibition against personal importation of prescription drugs.

The Drug Supply Chain Security Act (DSCSA), which requires the track and trace of prescription drugs from manufacturer to receipt by the dispenser, is undermined by drug importation, notes the letter. Importation proposals fail to align with track and trace requirements of the DSCSA in addition to other DSCSA requirements involving licensure of supply chain participants, verification and validation of drug products, and the handling of suspect and illegitimate products. The letter states, “broad importation and HHS waiver of importation prohibitions create loopholes within the DSCSA regulatory framework, easily allowing counterfeit drugs to slip into the United States supply chain.

CLICK HERE TO CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off